Novel 17 beta -hydroxy-19-nor-steroids
Abstract
PROCEDURE TO PREPARE DERIVATIVES 17-BETA-OH-19-NOR-STEROIDS REPLACED IN 17-ALFA OF FORMULA: IN WHICH R '' REPRESENTS A RADICAL PROPYLL, PROPENYL, IODOETHYLENE, IODOETINYL OR -C = C-CH2HAL1, WHERE HAL1 REPRESENTS A CHLORINE, FLUOR OR SPARK ATOM, AS WELL AS HIS SALTS, IN WHICH A REACTIVATE IS REACTED BROMURATION OR CHLORIDE, SUCH AS TRIPHENYLPHOSPHINE WITH TETRABROMIDE OR CARBON TETRACLORIDE, IN THE PRESENCE OF A SOLVENT SUCH AS TETRAHYDROFURAN OR METHYLENE CHLORIDE, WITH THE FORMULA PRODUCT AND AFTER THE REACTION IS CONTINUED WITH A HALOGEN CHANGE REAGENT SUCH AS CESIO FLUORIDE OR POTASSIUM, IN THE PRESENCE OF ETER CORONA-18-6 IN ACETONITRILE. OTHER ROADS FOR THE PREPARATION OF SUCH COMPOUNDS ARE DESCRIBED, AS WELL AS THE OBTAINING OF PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. THE COMPOUNDS (I) ARE PARTICULARLY USEFUL AS ANTIGLUCOCORTICOIDS, ANDROGENS, ANTI-ANDROGENS AND ANTIPROGESTOMIMETICS.

Term
Term ended
Expired 29 December 2008, 17.7 years ago.
- Priority
- Filed
- Granted
- Expired
- Today
5 claims: 1 independent, 4 dependent
- 1REIVINDICACIONES 1. Un procedimiento de preparación de productos de formula (I):(I) en la que R' representa un radical propilo, un radical propenilo, un radical yodoetenilo, un radical yodoetinilo o un radical -C^C-H 2 Hal 1 , en el que Hal 1 representa un átomo de cloro, flúor o bromo, así como sus sales de adicion con ácidos minerales u organicos, caracterizado porque: (a) para preparar los productos de formula (I 2 a): (I2A) en la que Hal1 representa un atomo de bromo, cloro o fluor, se hace reaccionar un reactivo de bromuracion o cloruracion, tal como trifenil-fosfina con tetrabromuro o tetracloruro de carbono, en presencia de un disolvente tal como tetrahidrofurano o cloruro de metileno, con el producto de formula (P 1 ): para obtener el producto de formula (I2A)enqueHal1 representa un atomodebromoodecloro,y despues se hace reaccionar con este ultimo producto un reactivo de cambio de bromo o de cloro por fluor, tal como fluoruro de cesio o fluoruro de potasio, en presencia de eter-corona 18-6 en acetonitrilo;(b) para preparar los productos de formula (I2B):
- 22 012 197 en la que el doble enlace es de configuracion E o Z, se hace reaccionar, con un producto de fórmula (P 2 ):(P2) en que K representa un grupo cetóonico protegido, por ejemplo un grupo etilendioxi, un agente reductor tal como hidruro de tributilestaño, bien en condiciones de radicales, en presencia de azoisobutironitrilo por ejemplo, para obtener un doble enlace E, o bien en un disolvente polar apróotico, tal como hexametilfosfotriamida, para obtener un doble enlace Z, y despuóes un agente de yoduracióon tal como N-yodosuccinimida, para obtener, tras eliminacioón del grupo protector, los productos de fóormula (I2B) en los que el doble enlace es de configuracion E o Z;(c) para preparar el producto de fórmula (I 2 c): se hace reaccionar, con un producto de foórmula (P3): 2 012 197 un reactivo de yoduración tal como N-yodosuccinimida, en presencia de una sal de plata tal como carbonato o nitrato de plata, para obtener el producto de formula (I 2 c);(d) para preparar los productos de fóormula (I2D): en la que la linea de trazos indica la presencia, entre los carbonos que la llevan, de un enlace sencillo o un enlace doble (Z), se hace reaccionar con el producto de fóormula (P4): hidroógeno en presencia de un catalizador tal como paladio sobre sulfato de bario, parcialmente envenenado con una amina tal como piridina o trietilamina, para obtener como producto principal el producto de fóormula (I2D)enelquelalóinea de trazos indica la presencia de un segundo enlace (Z), y como producto secundario el producto en el que la lóinea de trazos indica la presencia de un enlace sencillo. 2. Un procedimiento seguón la reivindicacióon 1, para la preparacioón de productos que tienen la foórmula (I2A): 2 012 197 en la que Hal1 representa un óatomo de bromo, cloro o fluóor, caracterizado porque se hace reaccionar un reactivo de bromuracioón o cloruracioón, tal como trifenil-fosfina con tetrabromuro o tetracloruro de carbono, en presencia de un disolvente tal como tetrahidrofurano o cloruro de metileno, con el producto de foórmula (P1): para obtener el producto de fóormula (I2A) en que Hal1 representa un aótomo de bromo o de cloro, y despuóes se hace reaccionar con este uóltimo producto un reactivo de cambio de bromo o de cloro por fluóor, tal como fluoruro de cesio o fluoruro de potasio, en presencia de óeter-corona 18-6 en acetonitrilo;
- 3Un procedimiento seguón la reivindicacioón 1, para la preparacióon de productos que tienen la fóormula (I 2B ):en la que el doble enlace es de configuracióon E o Z, se hace reaccionar, con un producto de foórmula (P2): 2 012 197 en que K representa un grupo cetóonico protegido, por ejemplo un grupo etilendioxi, un agente reductor tal como hidruro de tributilestaño, bien en condiciones de radicales, en presencia por ejemplo de azoisobutironitrilo por ejemplo, para obtener un doble enlace E, o bien en un disolvente polar aproótico, tal como hexametilfosfotriamida, para obtener un doble enlace Z, y despueós un agente de yoduracióon tal como N-yodosuccinimida, para obtener, tras eliminacióon del grupo protector, productos de fóormula (I2B en los que el doble enlace es de configuracioón E o Z.
- 4Un procedimiento seguón la reivindicacioón 1, para la preparacioón de productos que tienen la fóormula (I 2C ):caracterizado porque se hace reaccionar, con un producto de fórmula (P 3 ): un reactivo de yoduracióon tal como N-yodosuccinimida, en presencia de una sal de plata tal como carbonato o nitrato de plata, para obtener el producto de fóormula (I2C):
- 5Un procedimiento seguón la reivindicacióon 1 para la preparacioón de productos que tienen la fóormula (I2D):2 012 197 (I2D) en la que la lónea de trazos indica la presencia, entre los carbonos que la llevan, de un enlace sencillo o un enlace doble (Z), caracterizado porque se hace reaccionar con un producto de foórmula (P4): hidroógeno en presencia de un catalizador tal como paladio sobre sulfato de bario, parcialmente envenenado con una amina tal como piridina o trietilamina, para obtener como producto principal el producto de foórmula (I2D) en el que la lónea de trazos indica la presencia de un segundo enlace (Z), y como producto secundario el producto en el que la lónea de trazos indica la presencia de un enlace sencillo.
Independent claims5
178 paragraphs in 2 sections, as filed
DESCRIPTION
The subject of the present invention is a process for preparing compounds of formula (I):
<img file="ES2012197A6_D0001.tif" />
wherein R 'represents a propyl radical, a propenyl radical, a iodoetenyl radical, a radical-ethoethyl or a radical -C ^ CH<sub>2</sub>Hal<sub>1</sub>, in which Hal<sub>1</sub> It represents a chlorine, fluorine or bromine atom, as well as its additional salts with mineral or organic acids.
When R 'represents a iodoetenyl radical, the double bond is of configuration E or Z.
When R 'represents a propenyl radical, the double bond is of Z configuration.
The invention thus has, in particular, a process for preparing any one of the compounds of formula (I) as defined above, and whose names are as follows:
- alpha - (3-chloro-1-propynyl -) - 11-beta - [4 - (dimethyl-amino) phenyl] - 17-beta-hydroxy-ester
- 4,9-diene-3-one;
- beta - [4 - (dimethylamino) phenyl] - 17-alpha - (3-fluoro-1-propynyl) -17-beta-hydroxy-estra 4.9-dien-3-one;
- beta - [4 - (dimethylamino) phenyl] - 17-beta-hydroxy-21-iodo-19-nor-17-alpha-pregna 4,9,20-trien-3-one;
(E) 11-beta - [4 - (dimethylamino) phenyl] -17-beta-hydroxy-21-iodine-19-nor-17-alpha-pregna
- 4,9,20-trien-3-one;
(Z) 11-beta - [4- (dimethylamino) phenyl] -17-beta-hydroxy -21-iodo-19-nor-17-alpha-pregna 4,9,20-trien-3-one;
- beta - [4 - (dimethylamino) phenyl] - 17-beta-hydroxy-17-alpha - [(Z) -1-propenyl)-estra-4,9 diene-3-one;
- beta - [4 - (dimethylamino) phenyl] - 17-beta-hydroxy-17-alpha-propyl-estra-4,9-diene-3-one, and
- alpha - (3-bromo-1-propynyl) - 11-beta - [4 - (dimethyl-amino) phenyl] -17-beta-hydroxy estra-4,9-diene-3-one, as well as their salts addition with mineral or organic acids.
Among the preferred compounds obtained by the process following the invention, there may be mentioned especially:
- beta - [4-dimethylamino) phenyl] - 17-alpha - (3-fluoro-1-propynyl) - 17-beta-hydroxy-estra 4.9-dien-3-one, (Z) 11-beta - [4 - (dimethylamino) phenyl] - 17 - beta - hydroxy -21 - iodine - 19 - nor - 17 - alpha - pregna 4,9,20 - trien - 3 - one,
- beta - [4 - (dimethylamino) phenyl] - 17-beta-hydroxy-17-alpha - [(Z) -1-propenyl] estra-4,9 diene-3-one.
012 197
As addition salts of the products of formula (I) with acids, hydrochlorides and methanesulfonates can be mentioned in particular.
The products obtained by the process according to the invention, as well as their addition salts with pharmaceutically acceptable acids, are particularly interesting products from a pharmacological point of view; they have in particular a remarkable antiglucocorticoid activity.
The products obtained following the process of the invention also show androgenic or anti-androgenic properties.
The study of the products has also revealed a remarkable antiprogestomimotic activity.
The products obtained followed the process object of the invention, as well as their additional salts with pharmaceutically acceptable acids, can therefore be used to mainly combat the side effects of glucocorticoids; They also allow to combat disorders due to hypersecretion of glucocorticoids, and particularly aging in general, and particularly hypertension, atherosclerosis, osteoporosis, diabetes, obesity, as well as decreased immunity and insomnia.
The products of formula (I) obtained according to the process object of the invention, as well as their addition salts with pharmaceutically acceptable acids, which have antiprogestomimetic properties, can be used to prepare original contraceptives; they can also be used against hormonal disorders, and on the other hand, they may have an interest in the treatment of hormone-dependent cancers.
The products of formula (I) obtained according to the process object of the invention, as well as their additive salts with pharmaceutically acceptable acids, can also show progestomimotic properties, and can also be used in the treatment of amenorrhoea, dysmenorrhoea or luteal insufficiencies.
The pharmaceutically acceptable formula (I) products, that is to say non-toxic at the doses used, as well as their addition salts with pharmaceutically acceptable acids, and more particularly the preferred products mentioned above, ie the products of examples 2.5 and 6 (product A) pharmaceutically acceptable can thus be used as medicines.
The useful dosage varies depending on the condition to be treated and the route of administration; it may vary, for example, from 10 mg to 1 g, and preferably from 100 mg to 1 g per dose orally, for adults.
The products obtained followed the procedure object of the present invention, as well as their additive salts with pharmaceutically acceptable acids, which have antiprogestomimotic properties, can also be used as abortifacient in the veterinary field, and have a particular interest in cats and dogs.
The formula products (I), as well as their additional salts with pharmaceutically acceptable acids, and particularly the preferred products mentioned above, and most particularly the 11-beta - [4 (dimethylamino) phenyl] -17-beta-hydroxy-17 - alpha - [(Z) - 1-propenyl] estra-4,9-diene-3-one can therefore be used as veterinary drugs.
The useful dosage varied depending on the route of administration and the animal to be treated.
It can be 3 to 5 mg / kg live weight, in 1, 2 or 3 injections in 24 hours interval, and for example 5 mg / kg live weight in 2 injections in 24 hours interval in dogs using the product of example 6 (product A).
The compounds of formula (I), as well as their additive salts with pharmaceutically acceptable acids, can be used to prepare pharmaceutical compositions containing them as active ingredient.
The formula compounds (I), as well as their additive salts with pharmaceutically acceptable acids, and especially 11-beta - [4 - (dimethylamino) phenyl] - 17 - beta - hydroxy - 17 - alpha - [(Z) - 1 propenyl] estra-4,9-diene-3-one can be used to prepare pharmaceutical compositions for veterinary use which contain them as active ingredient.
012 197
The products of formula (I) obtained according to the process object of the invention, and their salts, can be used digestively, parenterally or locally. They can be prescribed in the form of tablets, simple or grageified, gelatin capsules, granules, suppositories, injectable preparations, ointments, creams, gels, which are prepared according to the usual methods.
The active ingredient (s) may be incorporated therein into excipients that are commonly used in pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, vegetables, aqueous or not, fatty substances of origin. animal or vegetable, paraffinic derivatives, glycols, various wetting agents, dispersants or emulsifiers, and preservatives.
The preparation process of the formula compounds (I), object of the invention, is characterized in that:
a) to prepare the formula products (I2A):
<img file="ES2012197A6_D0002.tif" />
wherein Hal1 represents a bromine, chlorine or fluorine atom, a bromination or chlorination reagent, such as triphenyl phosphine is reacted with tetrabromide or carbon tetrachloride, in the presence of a solvent such as tetrahydrofuran or methylene chloride, with the product of formula (P<sub>1</sub>):
<img file="ES2012197A6_D0003.tif" />
in order to obtain the product of foyrolum (I2A) in which Hal1 represents an atomodebromoodechloro, and then a bromine or chlorine exchange reagent is reacted with this latter product, such as cesium fluoride or potassium fluoride, in the presence of ether-crown 18-6 in acetonitrile;
(b) to prepare the formula products (I2B):
(See formula on the following page):
012 197
<img file="ES2012197A6_D0004.tif" />
in which the double bond is of E or Z configuration, it is reacted with a product of formula (P<sub>2</sub>):
<img file="ES2012197A6_D0005.tif" />
wherein K represents a protected ketone group, for example an ethylenedioxy group, a reducing agent such as tributyl ethane hydride, either under radical conditions, in the presence for example of azoiso butyronitrile to obtain a double bond E, or in a polar solvent approximative, such as hexamethylphosphotriamide, to obtain a double Z bond, and then an iodination agent such as N-iodosuccinimide, to obtain, after removal of the protective group, products of formula (I2B) in which the double bond is of configuration E or Z;
c) To prepare the formula product (I2C):
<img file="ES2012197A6_D0006.tif" />
It is reacted with a product of formula (P3):
012 197
<img file="ES2012197A6_D0007.tif" />
a iodination reagent such as N-iodosuccinimide, in the presence of a silver salt such as carbonate or silver nitrate, to obtain the formula product (I2C): d) to prepare the products of formula (I<sub>2D</sub> ):
<img file="ES2012197A6_D0008.tif" />
in which the dashed line indicates the presence, between the carbons that carry it, of a single bond or a double bond (Z), is reacted with a product of formula (P<sub>4</sub>):
<img file="ES2012197A6_D0009.tif" />
hydrogen in the presence of a catalyst such as palladium on barium sulfate, partially poisoned with an amine such as pyridine or triethylamine, to obtain as a main product the product of the formula (I2D) in the strokes indicates the presence of a second bond (Z), and as a secondary product the product in which the dashed line indicates the presence of a single link.
The product P1 is described in French patent 2,566,779; P2 and P3 products are described in European patent 0.057.115, and product P4 is described in French patent 2,497,807. The products of formula (I) are included in the general formula of European Patent No. 0,057,115, although not described therein.
012 197
The following examples illustrate the invention, but without limiting it.
Example 1: 17-alpha - (3-chloro-1-propynyl) -11-beta - [4 - (dimethylamino) phenyl] -17-beta-hydroxy-estra -4,9-diene-3-one.
800 11-beta - [4 - (dimethylamino) phenyl] - 17-beta-hydroxy-17-alpha - (3-hydroxy-1 propynyl)-estra-4,9-dien-3-one described in the French patent 2,566,779, are dissolved in 8 ml of tetrahydrofuran and 8 ml of carbon tetrachloride. 950 mg of triphenylphosphine are added and stirred at 90<sup>or</sup> C for 3 hours. A slight amount of insoluble material is filtered off, and the filtrate is evaporated to dryness. 1.40 g of crude product are recovered. The product is purified by silica column chromatography, eluting with petroleum ether mixture (eb. 40-70<sup>or</sup>C - ethyl acetate (50/50). 420 mg of pure chlorinated product are collected, in the form of crystalline solid.
Pf = 238<sup>or</sup>C.
IR spectrum (CHCl3):
OH 3600 cm<sup>-1</sup> C = O conjugate: 1655 cm<sup>-1</sup>
C = C conjugated and aromatic 1612/1562/1518 cm<sup>-1</sup>
Example 2: 11-beta - [4 - (dimethylamino) phenyl] -17-alpha - (3-fluoro-1-propynyl) -17-beta-hydroxy-estra -4,9-dien-3- ona.
313 17-alpha - (3-chloro-1-propynyl) -11-beta - [4 - (dimethylamino) -phenyl] -17-beta hydroxy-estra-4,9-dien-3-one agitate in 10 mg ml of dry acetonitrile with 600 mg of potassium fluoride and 600 mg of crown ether 18-6, heated to 90<sup>or</sup>C in inert atmosphere. After 23 hours of reflux, the solvent is evaporated, the residue is taken up in water and extracted with ethyl acetate. After washing with salt water and drying over magnesium sulfate, the organic phase evaporates. 322 mg of crude fluorinated product are collected. The crude product is purified by solid column chromatography, eluting with a mixture of methylene chloride / ethyl acetate, 90/10. 79 mg of pure product are collected, which are recrystallized from a mixture of methylene chloride and isopropyl ether to obtain 55 mg of the desired product. P. f. = 234-235<sup>or</sup>C.
IR spectrum (CHCl3)
OH 3600 cm<sup>-1</sup> C = O conjugate: 1655 cm<sup>-1</sup>
C = C conjugate + aromatics 1612/1562/1518 cm<sup>-1</sup>
Example 3: 11-beta - [4 - (dimethylamino) phenyl] -17-beta-hydroxy-21-iodo-19-nor-17-alpha pregna-4,9-dien-20-in-3-one
975 mg of 11-beta - [4 - (dimethylamino) -phenyl] -17-beta-hydroxy-19-nor-17 alpha-pregna-4,9-diene-20-in-3-one is dissolved in 20 ml of acetone, 640 mg of silver carbonate are added and then 450 mg of N-iodosuccinimide. It is stirred for 4 hours, the reaction mixture is poured into a 10% aqueous solution of sodium thiosulfate, and extracted with methylene chloride. The organic phase is washed with water, dried and evaporated to dryness. 1.2 g of crude product are obtained. The latter is chromatographed on solid, eluting first with a mixture of cyclohexane-ethyl acetate (6-4), and 390 mg of the desired product is obtained and 760 mg of mixture, which is chromatographed on solid, eluted with a mixture of hexane-ether (3-7), to obtain 530 mg of the product sought. The 920 mg of product obtained is crystallized in ether and 730 mg of product are obtained (mp about 210<sup>or</sup>C, and then 79 mg of supplemental product from the mother liquor.
IR spectrum (CHCl3)
OH 3598 cm<sup>-1</sup>
C = C 2174 cm<sup>-1</sup>
Dienone 1654 cm<sup>-1</sup>
Aromotic 1612/1562 / 1518cm<sup>-1</sup>
Example 4: (E) 11-beta - [4 - (dimethylamino) phenyl] -17-beta-hydroxy-21-iodine-19-nor-17-alpha-pregna-4,9,20-trien-3-one
Stage A: (E) (1,2-ethanediyl) 5-alpha, 17-beta-dihydroxy-11-beta - [4 - (dimethyla7)
012 197 min) phenyl] - 21 - iodine - 19 - nor - 17 - alpha - pregna - 9.20 - dien - 3 - one.
1) 1.5 g of 5-alpha, 17-beta-dihydroxy-11-beta [4 (dimethylamino) -phenyl] -19-nor-17-alpha-pregna cyclic (1,2-ethanediyl) acetal are dissolved - 9 - en - 20 - in -3 - one in 30 ml of anhydrous tetrahydrofuran, 8 ml of tributyltin hydride and 300 mg of azoisobutyronitrile are added, and heated at reflux for 50 minutes. It is concentrated under reduced pressure and the residual oil diluted in methylene chloride is chromatographed on solid. It is eluted with a mixture of cyclohexane-ethyl acetate (7-3) and 2.96 g of intermediate derivative of tributilestannilvinyl are collected.
2) It is dissolved in 30 ml of anhydrous tetrahydrofuran, 900 mg of N-iodosuccirnmide are added. After 25 minutes of reaction the reaction mixture is poured into a 10% aqueous solution of sodium thiosulfate, and extracted with methylene chloride. The orgaonic phase is washed with water, dried and evaporated to dryness. The residue is filled with reflux isopropyl ether, and then cooled with ice, and filtered with suction. 1.66 g of the product sought are obtained. P. f. = 246<sup>°</sup>C.
IR spectrum (CHCl3)
OH free: 3600 cm<sup>-1</sup>
OH in 5: 3500 cm<sup>-1</sup>
Aromatic: 1613/1517 cm<sup>-1</sup>.
Stage B: (E) 11-beta - [4 - (dimethylamino) phenyl] - 17-beta-hydroxy -21-iodine-19 nor-17-alpha pregna-4,9,20-trien-3-one.
1.66 g of the product obtained in A are dissolved in 16 ml of methanol and 16 ml of 2N hydrochloric acid. The solution is left for 1 hour at room temperature, the reaction mixture is poured into an aqueous solution of sodium bicarbonate, filtered and the precipitate is dissolved again in methylene chloride. The orgaonic phase is dried and evaporated under reduced pressure. The residue is chromatographed on solid, eluted with a mixture of cylcohexane-ethyl acetate (7-3) and 1.28 g of the expected crude product is collected. After dissolution in methylene chloride, concentration and then crystallization by the addition of ether, 1,125 g of the desired product are obtained. P. f. = 236<sup>°</sup>C after recrystallization from ethanol.
IR spectrum (CHCl3)
Dienone C = O: 1654 cm<sup>-1</sup>
C = C): 1612 cm<sup>-1</sup>
Aromotic (: 1518 cm<sup>-1</sup>
OH: 3600 cm<sup>-1</sup>
Example 5: (Z) 11-beta - [4 - (dimethylamino) phenyl] -17-beta-hydroxy-21-iodo-19-nor-17-alpha-pregna-4,9,20-trien-3-one .
Stage A: (Z) (1,2-ethanediyl) cyclic acetal of 5-alpha, 17-beta-dichydroxy-11-beta - [4 - (dimethylamino) phenyl] -21-tributilestannil-19-nor-17-alpha - pregna - 9,20 - dien - 3 - one.
477 mg of 5-alpha, 17-beta-dihydroxy-11-beta - [4-1,2-ethanediyl) acetal cyclic solution are dissolved
- (dimethylamino) phenyl] - 19-nor-17-alpha-pregn-9-en-20-in-3-one and in 5 ml of hexamethylphosphorotriamide, 2.6 ml of tributyl ethane hydride is added in an inert atmosphere, and it is heated at 70 ° C for 25 hours. It was cooled, diluted with water and extracted with ethyl acetate. The orgaonic phase is washed with water, dried and concentrated to dryness. The residue was chromatographed on solid, eluted with a mixture of petroleum ether (eg 40-70<sup>°</sup>C) - ether (6-4) and 214 mg of isomer E is collected, 135 mg of mixture of isomers E and Z, and 346 mg of the desired isomer (Z).
Stage B: (Z) 11-beta - [4 - (dimethylamino) phenyl] -17-beta-hydroxy-21-iodine-19-nor-17-alpha pregna-4,9,20-trien-3-one.
1.47 g of the isomer (Z) obtained in A is dissolved in 30 ml of leiraliidroinra.no, and 520 mg of N-iodosuccinimide are added with stirring. After 30 minutes at room temperature, the reaction mixture was poured into an aqueous solution of sodium thiosulfate and extracted with ethyl acetate. The organic phase is washed with water, dried and concentrated to dryness. 10 ml of methanol with 10 ml of 2N hydrochloric acid are added to the residue obtained, and it is allowed to react for 1 hour. It is made alkaline with a solution of sodium bicarbonate and extracted with methylene chloride. The organic phase is washed with water,
012 197 is dried and then concentrated to dryness to obtain 1.36 g of crude product. The residue is chromatographed on solid, eluted with a mixture of cyclohexane-ethyl acetate and 600 mg of the desired product is separated. P. f. = 178<sup>or</sup>C after crystallization in ether.
IR spectrum (CHCl3
Region C = O: 1650 cm<sup>-1</sup>
C = C: 1612 cm<sup>-1</sup>
Aromotic: 1518 cm<sup>-1</sup>
OH: 3590 cm<sup>-1</sup> and 3540 cm<sup>-1</sup>
Example 6: (Z) 11-beta - [4 - (dimethylamino) phenyl] -17-beta-hydroxy-17-alpha - [(Z) -1-propenyl] -estra-4,9-dien-3- one (product A) and 11-beta - [4 - (dimethylamino) phenyl] -17-beta-hydroxy-17-alpha-propyl-estra-4,9-diene-3-one (product B).
g of 11-beta - [4 - (dimethylamino) phenyl] - 17-beta-hydroxy-17-alpha - (1-propynyl)-estra-4,9
-dien-3-one is dissolved in 50 ml of ethanol and 1 ml of triethylamine, and 75 mg of 10% palladium hydroxide are added on barium sulfate. The mixture is hydrogenated at ordinary temperature, and is finished once absorbed 55 cm<sup>3</sup> of hydrogen. The catalyst is filtered, washed with ethanol and then the solvents are evaporated. 1,076 g of crude product are collected and chromatographed on a solid column (eluent: cyclohexane-ethyl acetate, 70-30). They are obtained successively:
mg of (Z) 11-beta - [4 - (dimethylamino) phenyl] -17-beta-hydroxy -17-alpha - [(Z) -1-propenyl] estra-5 (10) -en-3-one ( Rf: 0.40),
568 mg of (Z) 11-beta - [4 - (dimethylamino) phenyl] - 17-beta-hydroxy-17-alpha - [(Z) -1-propenyl]
- estra-4,9-dien-3-one (Rf: 0.27) (product A), and mg of 11-beta - [4 - (dimethylamino) phenyl] -17-beta-hydroxy-17-alpha- propyl-estra-4,9 dien-3-one (Rf: 0.24) (product B).
Physicochemical constants of product A
Analysis: C<sub>29</sub>H<sub>37</sub>DO NOT<sub>2</sub> = 431,63
Calculated:% C 80.70;% H 8.64;% N 3.25.
Found: 80.34 8.7 3.2
IR spectrum (CHCl3)
OH in 3608 cm<sup>-1</sup>
C = O and C = C conjugated 1654/1612 cm<sup>-1</sup>; C = O / C = C conjugated 1654/1612 cm<sup>-1</sup>
Aromotic 1580/1518 cm<sup>-1</sup>.
UV spectrum (EtOH)
Max. 258 nm = 17900
Max. 303 nm = 22700 + HCl0.1N, modem = 301 nm, 21300.
Physicochemical constants of product B
IR spectrum (CHCl3)
OH in 3615 cm<sup>-1</sup>; C = O / C = C conjugated 1654/1612 cm<sup>-1</sup>
Aromatic 1560/1518 cm<sup>-1</sup>
Example 7: 17-alpha - (3-bromo-1-propynyl) -11-beta - [- (dimethylamino) phenyl] -17-beta-hydroxy-estra-4,9-dien-3-one.
600 11-beta - [4 - (dimethylamino) phenyl] - 17-beta-hydroxy-17-alpha - (3-hydroxy-1-propynyl) estra-4,9-dien-3-one dissolved in 6 ml of methylene chloride with 491 mg of carbon tetrabromide. The solution is cooled to -10<sup>or</sup>C. A solution of 531 mg of triphenylphosphine in 3 ml of methylene chloride is then added dropwise. The mixture is stirred for 20 minutes at -10<sup>or</sup>C. It is available
012 197 afterwards, as it was, on a 15 g column of silica, and eluted with a mixture of petroleum ether (e.g. 40-70 C) / ethyl acetate, 50/50. 384 mg of pure brominated product are collected in the form of crystallized sylido.
Pharmaceutical compositions
Tablets are prepared that respond to the following formulation:
- Product of example 6 (Product A) 200 mg
- Excipient, cs for a finished tablet of 350 mg (Detail of the excipient: talc, starch and magnesium stearate)
Veterinary Composition
An injectable solution is prepared with the following formulation:
- Product of example 6 (Product A) 100 mg
- 0.3 ethanol
- Peanut oil csp 3 ml.
PHARMACOLOGICAL STUDY OF THE PRODUCTS OF THE INVENTION
I / Study of the activity of the products of the invention on hormonal receptors:
Rabbit uterus progestogen receptor
Some impubic rabbits of about 1 kg receive a cutaneous application of 25 g of estradiol. 5 days after this treatment the animals are sacrificed, the uterus are removed, weighed and homogenized at 0 ° C, with the help of a "Potter" of teflon-glass in a buffered TS solution (10 mM Tris, 0 sucrose, 25 M, Hcl pH 7.4) (1 g of tissue per 50 ml of TS). The homogenate is then ultracentrifuged (105,000 gx 90 min). Aliquots of the supernatant material thus obtained are incubated at 0<sup>°</sup>C for a time t, with a constant concentration (T) of tritiated product R (17,21-dimethyl-19-nor-4,9-pregnadien-3,20-dione) in the presence of increasing concentrations (0 to 2500. 10<sup>-9</sup> M), either R cold, cold progesterone, or cold product to be tested. The concentration of fixed tritiated R (B) in each incubation is then measured by means of carbon adsorption-dextran technique.
Rat Thymus Glucocorticoid Receptor
Sprague-Dwley EOPS male rats, weighing 160 to 200 g, are suprenalectomized. From 4 to 8 days after this ablation the animals are sacrificed, and the scams are extracted and homogenized at 0<sup>°</sup>C in a 10mM Tris buffer, 0.25M sucrose, 2mM dithiothreitol, HCl pH 7.4, with the aid of a "Potter" of polytetrafluoroethylene-glass (1 g of tissue with 10 ml of TS). The homogenate is then ultracentrifuged (105,000 gx 90 min.) At 0<sup>°</sup>C. Aliquots of the supernatant material thus obtained are incubated at 0<sup>°</sup>C for a time (t) with a constant concentration (T) of tritiated dexamethasone, in the presence of increasing concentrations (0 to 2500.<sup>-9</sup> M), either of cold dexamethasone, or of the product to be tested cold. The concentration of fixed tritiated dexamethasone (B) in each incubation is then measured by the adsorption technique in carbon-dextran.
Relative affinity binding link
The calculation of the relative binding affinity (ARE) is identical for all receivers.
The following 2 curves are drawn: both percent of the tritiated hormone T as a function of the locus of the concentration of the cold reference hormone, and T as a function of the logarithm of the concentration of the tested cold product.
Equation line I is determined<sup>50</sup> = (T max + T min) / 2
T max. = Both percent of the tritiated hormone bound for an incubation of this tritiated hormone at concentration (T).
012 197
T min = Percentage of bound tritiated hormone for an incubation of this tritiated hormone at concentration (T) in the presence of a large excess of cold hormone (2500. 10<sup>-9</sup> M).
The intersections of the I50 line and the curves allow the concentrations of the cold reference hormone (CH) and the cold product tested (CX) to be evaluated that inhibit the binding of the tritiated hormone to the receptor by 50%.
The relative binding affinity (ARE) of the product tested is determined by the equation:
ARE = 100 CH
The results obtained are the following:
<td rowspan="3">Products of the examples</td><td colspan="4">Incubation time at 0 ° C</td>
<td colspan="2">Progestogen</td><td colspan="2">Glucocorticoid</td>
<td>2H</td><td>24h</td><td>4H</td><td>24h</td>
<td> 1</td><td> 72</td><td> 286</td><td> 139</td><td> 159</td>
<td> 5</td><td> 41</td><td> 184</td><td> 145</td><td> 113</td>
<td>6 (product A)</td><td> 96</td><td> 491</td><td> 147</td><td> 115</td>
Abortion activity in female dogs
Preparation of the solution of the product to be studied
250 mg of the product to be studied are dissolved in 1 ml of methylene chloride, and then 1 ml of this solution is diluted in sesame oil, until 250 ml of final solution is obtained.
The state of pregnancy of female dogs from 16 months to 4 years of age is determined by ultrasound, and the duration of pregnancy that is extended from 25 to 40 days is recorded.
The product to be studied is administered, in solution corresponding to the previous preparation, subcutaneously at a dose of 5 mg / kg and 2 injections were made in 24 hours interval.
A control ultrasound was performed 3 to 10 days after the last injection.
3 days after the injection of the product of example 6 (product A) an abortion is checked in 66% of the cases.
days after the injection of the product of example 6 (product A) a complete abortion is verified in all the animals of the group.
Abortive activity in rabbits
Some rabbits receive, 10 days after fertilization, a subcutaneous injection of the product to be studied, at the corresponding concentration to the previous preparation, in a dose of 4 mg / kg and 5 mg / kg.
days after this treatment the animals are sacrificed and the number of abortions verified at autopsy is observed.
A complete abortion is verified in all the animals of the group with the product of example 6 (product A) administered in a dose of 4 mg / kg and a dose of 5 mg / kg.
012 197
Contents2
9 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9
101 members in 32 offices
Priority claims5
| Document | Office | Kind | Date |
|---|---|---|---|
| 19870018376 | France | – | |
| 8718376 | France | A | |
| 8718376 | France | A | |
| 8718376 | – | – | – |
| FR19870018376 | – | – | – |
Members101
| Document | Office | Kind | |
|---|---|---|---|
| PT74263A | Portugal | A | |
| IE820044L | Ireland | L | |
| DK4082A | Denmark | A | |
| FI820042L | Finland | L | |
| AU7929682A | Australia | A | |
| FR2497807A1 | France | A1 | |
| EP0057115A2 | European Patent Office (EPO) | A2 | |
| EP0057115A3 | European Patent Office (EPO) | A3 | |
| JPS57168000A | Japan | A | |
| ZA8231B | South Africa | B | |
| ES508588A0 | Spain | A0 | |
| ES8305786A1 | Spain | A1 | |
| US4386085A | United States of America | A | |
| FR2497807B1 | France | B1 | |
| ES517764A0 | Spain | A0 | |
| ES8401498A1 | Spain | A1 | |
| FR2528434A1 | France | A1 | |
| EP0097572A1 | European Patent Office (EPO) | A1 | |
| KR840000581A | Republic of Korea | A | |
| JPS5946299A | Japan | A | |
| US4447424A | United States of America | A | |
| EP0110434A1 | European Patent Office (EPO) | A1 | |
| HU185158B | Hungary | B | |
| EP0057115B1 | European Patent Office (EPO) | B1 | |
| AT12239T | Austria | T | |
| ATE12239T1 | Austria | T1 | |
| DE3262580D1 | Germany | D1 | |
| US4519946A | United States of America | A | |
| FR2528434B1 | France | B1 | |
| CA1193246A | Canada | A | |
| US4547493A | United States of America | A | |
| CA1199907A | Canada | A | |
| AU550334B2 | Australia | B2 | |
| AU5123685A | Australia | A | |
| EP0196707A1 | European Patent Office (EPO) | A1 | |
| EP0110434B1 | European Patent Office (EPO) | B1 | |
| EP0097572B1 | European Patent Office (EPO) | B1 | |
| AT23167T | Austria | T | |
| AT23344T | Austria | T | |
| ATE23167T1 | Austria | T1 | |
| ATE23344T1 | Austria | T1 | |
| DE3273985D1 | Germany | D1 | |
| DE3367396D1 | Germany | D1 | |
| US4634695A | United States of America | A | |
| US4634696A | United States of America | A | |
| CA1220780A | Canada | A | |
| KR870001936B1 | Republic of Korea | B1 | |
| SG45987G | Singapore | G | |
| IE52595B1 | Ireland | B1 | |
| AU579211B2 | Australia | B2 | |
| SU1447289A3 | Soviet Union (until 1991) | A3 | |
| IT8848730A0 | Italy | A0 | |
| IT8848730D0 | Italy | D0 | |
| SE8804692D0 | Sweden | D0 | |
| FI77872B | Finland | B | |
| GB8830380D0 | United Kingdom | D0 | |
| FI77872C | Finland | C | |
| LU87417A1 | Luxembourg | A1 | |
| SE8804692L | Sweden | L | |
| FR2625505A2 | France | A2 | |
| DE3844408A1 | Germany | A1 | |
| NL8803196A | Netherlands (Kingdom of the) | A | |
| GB2213484A | United Kingdom | A | |
| JPH01213296A | Japan | A | |
| EP0196707B1 | European Patent Office (EPO) | B1 | |
| AT46702T | Austria | T | |
| ATE46702T1 | Austria | T1 | |
| DE3380628D1 | Germany | D1 | |
| JPH01279897A | Japan | A | |
| ES2012197A6This record | Spain | A6 | |
| FR2640977A2 | France | A2 | |
| JPH0234958B2 | Japan | B2 | |
| US4978657A | United States of America | A | |
| CH676852A5 | Switzerland | A5 | |
| US5006518A | United States of America | A | |
| FR2625505B2 | France | B2 | |
| IL65680A | Israel | A | |
| US5043332A | United States of America | A | |
| GB2213484B | United Kingdom | B | |
| CA1303025C | Canada | C | |
| IT1235358B | Italy | B | |
| JPH0443077B2 | Japan | B2 | |
| JPH0466879B2 | Japan | B2 | |
| BE1004905A4 | Belgium | A4 | |
| ATA318788A | Austria | A | |
| DK166680B1 | Denmark | B1 | |
| AT396787B | Austria | B | |
| AR245730A1 | Argentina | A1 | |
| GR880100868A | Greece | A | |
| LT2618B | Lithuania | B | |
| MD207B1 | Republic of Moldova | B1 | |
| MD207C2 | Republic of Moldova | C2 | |
| BG60768B2 | Bulgaria | B2 | |
| SE503267C2 | Sweden | C2 | |
| GEP19960479B | Georgia | B | |
| JP2785023B2 | Japan | B2 | |
| DE19975073I1 | Germany | I1 | |
| NL300001I1 | Netherlands (Kingdom of the) | I1 | |
| NL300001I2 | Netherlands (Kingdom of the) | I2 | |
| DE3844408C2 | Germany | C2 |
2 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Patent lapsedLapsedFD1A | FD1A | |
| Expiration date (snapshot 920101)2008-12-29SA6 | SA6 |
Numbers
- Publication
- 2012197
- Publication, DOCDB
- 2012197
- Publication, EPODOC
- ES2012197
- Application
- 8804011
- Application, DOCDB
- 8804011
- Application, EPODOC
- ES19880004011
Titles2
- Spanish
- PROCEDIMIENTO PARA PREPARAR DERIVADOS 17-BETA-OH-19-NOR-ESTEROIDES SUSTITUIDOS EN 17-ALFA.
- English
- PROCEDURE TO PREPARE DERIVATIVES 17BETA-OH-19-NOR-STEROIDS REPLACED IN 17ALFA.
Classification
- CPC, 10
- C07J41/0033
- C07J41/0083
- A61P25/20
- A61P3/04
- A61P3/06
- A61P3/08
- A61P43/00
- A61P9/10
- A61P9/12
- A61P3/10
- IPC, 11
- A61K31 57
- A61K31 575
- A61P3 04
- A61P3 06
- A61P3 08
- A61P3 10
- A61P9 10
- A61P9 12
- A61P25 20
- A61P43 00
- C07J41 00